Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement

Core Insights - Spartan Capital Securities, LLC successfully completed two private placements for Lipella Pharmaceuticals Inc., raising a total of $875,500 through the issuance of Series B non-voting convertible preferred stock [1][2][3] Company Overview - Lipella Pharmaceuticals, led by CEO Jonathan Kaufman, focuses on developing therapies to address significant unmet medical needs [2][3] - Spartan Capital Securities serves as a full-service investment banking firm, providing advisory services and capital raising expertise [7] Transaction Details - The proceeds from the private placements will be utilized to advance Lipella's clinical pipeline and for general corporate purposes [2] - The transactions were completed under customary closing conditions, with Sichenzia Ross Ference Carmel LLP and Sullivan & Worcester LLP providing legal counsel [3][4] Regulatory Information - The common shares and related warrants from the private placements have not been registered under the Securities Act of 1933, and cannot be offered or sold in the U.S. without registration or an exemption [5][6]